World Clinical Biomarkers and CDx Summit on September 22-25, 2025 in Boston, United States

Driven by advancements in genomic profiling, omics, and AI technologies, the biomarkers and diagnostics field continues to surge, with Roche and AstraZeneca's world-first digital pathology CDx approval in April taking the number of approved CDx tests to a record high of 188.

We are now witnessing a need for new, stronger co-development partnerships to validate novel biomarkers, navigate global in vitro diagnostic regulation, and harmonize commercialization; which will in turn accelerate adoption of these drug-diagnostics across diverse therapeutic areas and markets.

Returning for its 15th anniversary this September, the World Clinical Biomarkers and Companion Diagnostics Summit will unite 600+ industry leaders across biopharma, CDx developers, testing labs, regulators, and payers to advance clinical biomarker strategies and accelerate drug-diagnostics to market for improved patient diagnosis, stratification, and monitoring.

Join us in celebrating 15 years of progress and be a part of the conversations and collaborations to define the next 15.

URLs:

Brochure: https://go.evvnt.com/3105616-0?pid=10008

Tickets: https://go.evvnt.com/3105616-2?pid=10008

Time: 8:00 AM - 6:00 PM

Prices:

Conference + up to 5 engagers - Drug Developer and Academic: USD 0.50,

Conference only - Drug Developer and Academic: USD 0.50,

Conference only - Solution and Service Provider: USD 3899.00

Speakers: Mark Gustavson, Senior Director and Head of Computational Pathology Strategic Partnerships, AstraZeneca, Geoff Oxnard, Chief Medical Officer, BlossomHill Therapeutics, Sarah Hersey, Vice President - Precision Medicine, Bristol Myers Squibb, Katia Bassett, Senior Director and Head of CDx Development, Translational Medicine, Genentech, Ben Withey, Director, Commercial Diagnostics, CDx Lead, Pfizer, Brian Lockhart, Global Head of Companion Diagnostics, Servier, Sally Werner, Chief Executive Officer, Cancer Support Community, Gabriel Bien-Willner, Chief Medical Officer, Palmetto GBA, Anthony Kanavage, IVD Product Assessment Team Manager, TÜV SÜD, Kevin Liang, Vice President, Optum Evidence Engine, UnitedHealth Group, Banu Sankaran, Head of Diagnostics Strategy and Development, Alexion Pharmaceuticals, Dishant Kalra, Head of Precision Medicine, Astellas Pharma, Cedric Dos Santos, Global Product Leader, AstraZeneca, Vasiliki Pelekanou, Senior Director - Digital Pathology, Oncology Precision Medicine Leader, Bayer, Kazuishi Kubota, Functional Excellence and Clinical Biomarker Oncology Department Head, Daiichi Sankyo, Andrea Renninger, Senior Director, Regulatory Affairs and Companion Diagnostics, Daiichi Sankyo, Ying Wu, Director and Head of Human Genetics, Eisai Co., Ltd., Susanne Rhoades, Associate Vice President, Diagnostic Development, Eli Lilly, Dun Liang, Global Regulatory Affairs, Diagnostics, Eli Lilly and Co., Zheng Feng, Director / Head of Clinical Genomics, EMD Serono, An affiliate of Merck KGaA, Darmstadt, Germany, Anupam Talapatra, Global Regulatory Director, Precision Medicine and Companion Diagnostics, Gilead Sciences, Tom Battersby, Executive Director, Biomarker-Research, Gilead Sciences, Andrea Belange,r Associate Director, Precision Medicine External Innovation, GlaxoSmithKline, Gabriele Allegri, Vice President, Global Commercial Precision Medicine, Johnson and Johnson, David Weingeist, Scientific Director, Oncology Precision Medicine and Diagnostics, Johnson and Johnson, Renee Yura, Executive Director, Clinical Biomarkers, Moderna, Irina Leaf, Director and Lead - Therapeutic Area Biomarker , Disease Area and Global Health, Novartis AG, Shelley Ann des Etages-Wong, Senior Director, Diagnostics PMO Lead, Pfizer, Jennifer Hamilton, Vice President and Head, Precision Medicine, Regeneron Pharmaceuticals, Brian Baker, Executive Director, Regulatory Affairs and In Vitro Diagnostics, Regeneron Pharmaceuticals, Gerard Sanderink, Vice President, Global Head Laboratory Sciences, Sanofi, Cheng Yang, Digital Diagnostics Lead, Takeda Pharmaceutical, Silva Krause, Executive Director and Head of Biomarkers, Vertex Pharmaceuticals, June Lu, Chief Scientific Officer, BeyondSpring Pharmaceuticals Inc., John Rossi, Vice President - Translational Medicine, Capstan Therapeutics, Mike Kagey, Vice President, Translational Medicine, Leap Therapeutics, Jorge DiMartino, Chief Medical Officer, Plexium Inc., Simon Beaulah, Senior Vice President, Healthcare and Head of US Operations, PrecisionLife Ltd., Brenton Mar, Senior Vice President and Head of Clinical Development, Relay Therapeutics, Sylvan Baca, Assistant Professor and Medical Oncologist, Dana-Farber / Harvard Cancer Center, Mark Stewart, Vice President, Science Policy, Friends of Cancer Research, Pedram Razavi MD, PhD Director, Liquid Biopsy and Cancer Genomics, MSK Biomarker Development Program, Memorial Sloan Kettering Cancer Center, Viktor Adalsteinsson, Director, Gerstner Center for Cancer Diagnostics, The Broad Institute of MIT and Harvard, Verena Aumiller, Vice President - Scientific Programs, Aignostics, Katarina Wikstrom, Global Vice President of Product Development, Almac, Lydia Tsai, Director - Business Development and Companion Diagnostics, Bio-Techne Corporation, Colin McDowell, Senior Manager - Business Development, Biodesix, Yiming Livelo, Translational Scientist, Burning Rock Biotech, Gulfem Guler, Vice President, Translational Research, Clear Note Health, Gary Potikyan, Chief Science Officer and Founder, EntroGen - Inc, Ali Kuraishy, Head and Clinical Business Development, Illumina, Inc., Siraj Ali, Global Vice President, Translation Medicine, Lunit, J Carl Barrett, Chief Scientific Officer, Precede Biosciences, Leila Luheshi, Vice President - Pharma Partnering, Sysmex Precision Medicine, David Chi, Senior Manager - Product, Thermo Fisher Scientific Inc